Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), filed a Form 4 on August 17, 2026, disclosing two rounds of stock option exercises and corresponding common stock sales on August 13 and August 17, 2026, pursuant to a previously adopted 10b5-1 trading plan.

Key Highlights

  • Two exercise-and-sell transactions: Bizily exercised 1,635 stock options and sold 1,635 shares on August 13, 2026, then repeated the same exercise and sale on August 17, 2026.
  • Option exercise price: Both sets of options were exercised at $4.14 per share.
  • Sale prices: The 1,635 shares sold on August 13 were sold at $12 per share; the 1,635 shares sold on August 17 were sold at $12.2 per share.
  • Remaining direct ownership: Following both transactions, Bizily directly held 8,617 shares of common stock.
  • Remaining options: After both exercises, 59,701 stock options remained beneficially owned directly by Bizily.
  • 10b5-1 plan: Both sales were made pursuant to a 10b5-1 trading plan adopted by Bizily on January 13, 2026.
  • Option vesting: The exercised options vest as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025, with full vesting on the fourth anniversary of that date.

Scott Bizily's Option Exercises and Share Sales at 4D Molecular Therapeutics

According to the filing, Scott Bizily, serving as Chief Legal Officer of 4D Molecular Therapeutics, Inc., executed two separate but identical-size transactions involving the company's common stock. On August 13, 2026, Bizily exercised stock options covering 1,635 shares at an exercise price of $4.14 per share (transaction code M), bringing his direct common stock holdings to 10,252 shares. He then sold those 1,635 shares (transaction code S) at $12 per share, reducing his direct holdings to 8,617 shares.

On August 17, 2026, the filing discloses that Bizily repeated the same sequence: he exercised an additional 1,635 options at $4.14 per share, again reaching 10,252 shares directly held, and immediately sold those 1,635 shares at $12.2 per share, returning his direct common stock position to 8,617 shares. Both sales are attributed to a 10b5-1 trading plan that Bizily adopted on January 13, 2026, according to the filing's footnote.

The filing notes that the underlying stock options carry an exercise price of $4.14 and an expiration date of March 5, 2035. The vesting schedule, as described in the filing, provides that shares vest at a rate of 1/48th of the total grant on each monthly anniversary of March 6, 2025, the stated vesting commencement date, "such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company." After both exercises, 59,701 stock options remained directly held by Bizily.

What Was Disclosed

The Form 4 reports two option exercise and share sale transactions by 4D Molecular Therapeutics' Chief Legal Officer on August 13 and August 17, 2026, each involving 1,635 shares exercised at $4.14 and sold under a 10b5-1 plan, leaving 8,617 shares and 59,701 options directly held.